ASH 2022 | Novel AI model for personalized risk stratification & treatment in newly diagnosed multiple myeloma
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some insights into a novel artificial intelligence (AI) model being used to individualize risk stratification and treatment approaches in patients with newly diagnosed multiple myeloma (NDMM). This model is dynamic and integrates several genomic and clinical factors, and Dr Landgren highlights future plans for this novel precision medicine tool. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials, Research Funding; Amgen: Research Funding; Merck: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials; Pfizer: Consultancy.
